About PhRMA
People of PhRMA
145 people are tracked at PhRMA (104 in leadership, 21 in board & advisors, 20 in team).
| Name | Role | Group |
|---|---|---|
Stephen J. Ubl | President & CEO | Leadership |
Charise Johnson | Sr. Director, State Policy | Leadership |
Eric Lohnes | Deputy Vice President, State Advocacy | Leadership |
Sarah Snyder Rayel | Deputy Vice President, Policy And Research | Leadership |
Jason Edgmon | Senior Director Of IT Infrastructure And Operations | Leadership |
Lauren Neves | Vice President, Policy And Research | Leadership |
Neil Pratt | Sr. Assistant General Counsel And Head Of Int'l Legal Affairs | Leadership |
Katie Fitzwilliam | Deputy Vice President | Leadership |
Jennifer Wolff Cline | Senior Director, Public Affairs And Advocacy | Leadership |
Elenora Connors | Deputy Vice President | Leadership |
Lori M. Reilly | COO | Leadership |
Lin Shi | Director, International Advocacy | Leadership |
Reid Porter | Senior Director Of State Relations | Leadership |
John Corea | Senior Director, Research | Leadership |
Rachel Weissman | Deputy Vice President | Leadership |
Alexandra Miller | Director, Advocacy & Strategic Alliances | Leadership |
Cara Toman | Chief Of Staff, Policy And Research And Board Of Directors | Leadership |
Elizabeth Carpenter | Executive Vice President, Policy And Research | Leadership |
Nancy Kelly | Senior Director Facilities | Leadership |
Scott Laganga | Executive Vice President, State Advocacy | Leadership |
125 more people are available in the full profile.
Complete people profiles for PhRMA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of PhRMA
PhRMA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Curia and AmplifyBio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novartis.com | 1996 | Basel, Switzerland | – | 97 | R&D focused on manufacturing of drugs for multiple therapeutic areas | |
| catalent.com | 2007 | Somerset, United States | – | 9,390 | CDMO offering drug and biologics development services | |
| surrozen.com | 2016 | San Francisco, United States | $133M | 80 | Selective Wnt agonists are developed for human tissue regeneration. | |
| curiaglobal.com | 1991 | Albany, United States | – | 1,918 | Drug research, development, testing, and consulting services are provided. | |
| amplify-bio.com | 2021 | Hilliard, United States | $229.75M | – | Provides contract research, development, and manufacturing services for biologic drugs. | |
| wuxibiologics.com | 2008 | Shanghai, China | – | 257 | Protein therapeutics are developed and manufactured by WuXi Biologics. | |
| samsungbiologics.com | 2011 | Incheon, South Korea | – | – | Contract development and manufacturing for biologics are provided. | |
| biotage.com | 2009 | Uppsala, Sweden | – | – | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | |
| indapta.com | 2016 | Seattle, United States | $72.5M | – | Limited information available |
Detailed competitors of PhRMA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PhRMA
The website of PhRMA (phrma.org) receives about 63.3K visits a month and ranks #555,565 among all websites worldwide, #582 in Biotechnology and Pharmaceuticals.
- Monthly visits63.3K
▼ 10.7% vs previous month
- Unique visitors43.6K
per month
- Global rank#555,565
among all websites
- Category rank#582
Health · Biotechnology and Pharmaceuticals
- Bounce rate65%
- Pages per visit1.5
- Average visit21 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with PhRMA. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| acaciapharma.com | 98% | – | – | View details | |
| novartis.com | 88% | 948.8K | #58,822 | View details | |
| purduepharma.com | 86% | 26.1K | #875,078 | View details | |
| efpia.eu | 86% | 89.3K | #445,999 | View details | |
| iqvia.com | 84% | 1.2M | #45,953 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for PhRMA
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Phrma
Complete news archive for PhRMA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to PhRMA
10 companies that operate in the same segment as PhRMA (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PhRMA
PhRMA was founded in 1994.
PhRMA delivers end-to-end solutions for drug development, including design, development, and supply services, focusing on providing healthcare solutions, producing pharmaceutical products, drug development, and research and supply. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets.